FDA PDUFA dates in October 2026
Published PDUFA target action dates for NDAs, BLAs, ANDAs, and INDs scheduled in October 2026, sourced from FDA primary records.
Tracking 10 published FDA PDUFA decisions, including 4 NDAs and 6 BLAs.
| Sponsor | Product | Type | Application | PDUFA date | Status | Ask, copy and expand |
|---|---|---|---|---|---|---|
| Merck and Eisai | WELIREG + LENVIMA | NDA | NDA 215383 SUPPL-13 | decided | ||
| Genentech (Roche) | Tecentriq (atezolizumab) | BLA | PENDING-provisional|genentechroche|tecentriqatezolizumab | overdue | ||
| Genentech (Roche) | Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) | BLA | PENDING-provisional|genentechroche|tecentriqhybrezaatezo | overdue | ||
| Daiichi Sankyo and Merck | ifinatamab deruxtecan | BLA | PENDING-provisional|daiichisankyoandmerck|ifinatamabderu | overdue | ||
| Genentech / Roche | Enspryng (satralizumab) | BLA | PENDING-provisional|genentechroche|enspryngsatralizumab| | overdue | ||
| Opus Genetics and Viatris | phentolamine ophthalmic solution 0.75% | NDA | PENDING-provisional|opusgeneticsandviatris|phentolamineo | overdue | ||
| PHARMING | JOENJA | NDA | NDA 217759 SUPPL-6 | decided | ||
| GSK | bepirovirsen | NDA | PENDING-provisional|gsk|bepirovirsen|chronichepatitisb|2 | overdue | ||
| Sun Pharmaceutical Industries | ILUMYA (tildrakizumab-asmn) | BLA | PENDING-provisional|sunpharmaceuticalindustries|ilumyati | overdue | ||
| INOVIO Pharmaceuticals | INO-3107 | BLA | PENDING-provisional|inoviopharmaceuticals|ino3107|recurr | overdue |
Select any row to expand its full record. Use the calendar, timeline, status board, or table views above to filter, sort, and inspect source-linked details.
October 2026 FDA PDUFA Calendar: Drug Approval Dates & Deadlines
Track October 2026 FDA review dates and drug approval decisions. Browse products, sponsors, application types, source-linked deadlines, and reported outcomes.
Loading calendar controls…
